JAK inhibition in hidradenitis suppurativa and vitiligo

Abstract

In recent years, Janus kinase (JAK) inhibitors have proven to be effective in several immune-mediated diseases. A deeper understanding of the pathomechanism of certain conditions continues to open up new indications for clinical practice. In the diseases-vitiligo and hidradenitis suppurativa- discussed in this publication, numerous clinical trials have evaluated their efficacy. Interestingly, in early-stages and limited cases, topical formulation instead of systemic administration appears to be promising. In the case of vitiligo, a topical JAK inhibitor has already been approved. In this publication, we summarize the ongoing studies for vitiligo and hidradenitis suppurativa.